COVID-19 UPDATE: We are open! Our team is working and offering consultations via phone, e-mail, and video conferencing.

FDA Adds New Information to Fosamax Label: Consumers May be at Risk of Atypical Bone Fractures

On October, 2010, the Food and Drug Administration (FDA) announced new information would be added to the Warnings and Precautions section of all bisphosphonate drugs approved for the prevention or treatment of osteoporosis, including Fosamax.

The warning came after new studies suggested the drug, manufactured by Merck & Co. and commonly used for the treatment of osteoporosis in postmenopausal women, may be linked to unusual fractures of the thigh, known as subtrochanteric and diaphyseal femur fractures.

But the concerns surrounding Fosamax do not end here. Reports indicate the drug also causes Osteonecrosis, a disfiguring condition caused by the rotting of the jaw. Indeed, for the last five years, Merck & Co. has had to defend a flood of lawsuits filed by osteonecrosis victims.

Severe digestive reactions, including:

  • Nausea
  • Heartburn
  • Stomach pain
  • Diarrhea
  • Muscle cramps
  • Blood clotting disorders

The FDA approved Fosamax in 1995, after medical trials demonstrated the drug’s efficacy substantially outweighed its then reportedly mild side effects. Today, however, the risks associated with Fosamax are many, and to keep patients informed, the FDA is requiring that all physicians hand their patients a medication guide explaining recent findings about Fosamax’s side effects.

For more information about Fosamax and any preventive measures visit If you need assistance with a consumer protection matter, reach out to our firm.


Our Firm Is Ready to Fight for You

    • Please enter your name.
    • Please enter your phone number.
      This isn't a valid phone number.
    • This isn't a valid email address.
      Please enter your email address.
    • Sign up for Future Communications
    • Please make a selection.
    • Please enter a message.
Put Us On Your Side